Current and emerging biologics for ulcerative colitis

Sung Chul Park, Yoon Tae Jeen

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Conventional medical treatment for ulcerative colitis can have limited efficacy or severe adverse reactions requiring additional treatment or colectomy. Hence, different biological agents that target specific immunological pathways are being investigated for treating ulcerative colitis. Anti-tumor necrosis factor (TNF) agents were the first biologics to be used for treating inflammatory bowel disease. For example, infliximab and adalimumab, which are anti-TNF agents, are being used for treating ulcerative colitis. Recently, golimumab, another anti-TNF agent, and vedolizumab, an anti-adhesion therapy, have been approved for ulcerative colitis by the U.S. Food and Drug Administration. In addition, new medications such as tofacitinib, a Janus kinase inhibitor, and etrolizumab, another anti-adhesion therapy, are emerging as therapeutic agents. Therefore, there is a need for further studies to select appropriate patient groups for these biologics and to improve the outcomes of ulcerative colitis treatment through appropriate medical usage.

Original languageEnglish
Pages (from-to)18-27
Number of pages10
JournalGut and Liver
Volume9
Issue number1
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Biological Products
Ulcerative Colitis
Tumor Necrosis Factor-alpha
Therapeutics
Janus Kinases
Colectomy
Biological Factors
United States Food and Drug Administration
Inflammatory Bowel Diseases

Keywords

  • Biological therapies
  • Ulcerative colitis

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Current and emerging biologics for ulcerative colitis. / Park, Sung Chul; Jeen, Yoon Tae.

In: Gut and Liver, Vol. 9, No. 1, 01.01.2015, p. 18-27.

Research output: Contribution to journalArticle

Park, Sung Chul ; Jeen, Yoon Tae. / Current and emerging biologics for ulcerative colitis. In: Gut and Liver. 2015 ; Vol. 9, No. 1. pp. 18-27.
@article{a406967797c345b0b48750cb42a45f64,
title = "Current and emerging biologics for ulcerative colitis",
abstract = "Conventional medical treatment for ulcerative colitis can have limited efficacy or severe adverse reactions requiring additional treatment or colectomy. Hence, different biological agents that target specific immunological pathways are being investigated for treating ulcerative colitis. Anti-tumor necrosis factor (TNF) agents were the first biologics to be used for treating inflammatory bowel disease. For example, infliximab and adalimumab, which are anti-TNF agents, are being used for treating ulcerative colitis. Recently, golimumab, another anti-TNF agent, and vedolizumab, an anti-adhesion therapy, have been approved for ulcerative colitis by the U.S. Food and Drug Administration. In addition, new medications such as tofacitinib, a Janus kinase inhibitor, and etrolizumab, another anti-adhesion therapy, are emerging as therapeutic agents. Therefore, there is a need for further studies to select appropriate patient groups for these biologics and to improve the outcomes of ulcerative colitis treatment through appropriate medical usage.",
keywords = "Biological therapies, Ulcerative colitis",
author = "Park, {Sung Chul} and Jeen, {Yoon Tae}",
year = "2015",
month = "1",
day = "1",
doi = "10.5009/gnl14226",
language = "English",
volume = "9",
pages = "18--27",
journal = "Gut and Liver",
issn = "1976-2283",
publisher = "Joe Bok Chung",
number = "1",

}

TY - JOUR

T1 - Current and emerging biologics for ulcerative colitis

AU - Park, Sung Chul

AU - Jeen, Yoon Tae

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Conventional medical treatment for ulcerative colitis can have limited efficacy or severe adverse reactions requiring additional treatment or colectomy. Hence, different biological agents that target specific immunological pathways are being investigated for treating ulcerative colitis. Anti-tumor necrosis factor (TNF) agents were the first biologics to be used for treating inflammatory bowel disease. For example, infliximab and adalimumab, which are anti-TNF agents, are being used for treating ulcerative colitis. Recently, golimumab, another anti-TNF agent, and vedolizumab, an anti-adhesion therapy, have been approved for ulcerative colitis by the U.S. Food and Drug Administration. In addition, new medications such as tofacitinib, a Janus kinase inhibitor, and etrolizumab, another anti-adhesion therapy, are emerging as therapeutic agents. Therefore, there is a need for further studies to select appropriate patient groups for these biologics and to improve the outcomes of ulcerative colitis treatment through appropriate medical usage.

AB - Conventional medical treatment for ulcerative colitis can have limited efficacy or severe adverse reactions requiring additional treatment or colectomy. Hence, different biological agents that target specific immunological pathways are being investigated for treating ulcerative colitis. Anti-tumor necrosis factor (TNF) agents were the first biologics to be used for treating inflammatory bowel disease. For example, infliximab and adalimumab, which are anti-TNF agents, are being used for treating ulcerative colitis. Recently, golimumab, another anti-TNF agent, and vedolizumab, an anti-adhesion therapy, have been approved for ulcerative colitis by the U.S. Food and Drug Administration. In addition, new medications such as tofacitinib, a Janus kinase inhibitor, and etrolizumab, another anti-adhesion therapy, are emerging as therapeutic agents. Therefore, there is a need for further studies to select appropriate patient groups for these biologics and to improve the outcomes of ulcerative colitis treatment through appropriate medical usage.

KW - Biological therapies

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=84919385044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919385044&partnerID=8YFLogxK

U2 - 10.5009/gnl14226

DO - 10.5009/gnl14226

M3 - Article

VL - 9

SP - 18

EP - 27

JO - Gut and Liver

JF - Gut and Liver

SN - 1976-2283

IS - 1

ER -